Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 418

1.

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.

Chow LQ, Eckhardt SG, O'Bryant CL, Schultz MK, Morrow M, Grolnic S, Basche M, Gore L.

Cancer Chemother Pharmacol. 2008 Sep;62(4):631-46. Epub 2007 Dec 6.

PMID:
18058098
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.

Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK.

Clin Cancer Res. 2004 May 1;10(9):2968-76.

PMID:
15131032
[PubMed - indexed for MEDLINE]
Free Article
3.

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.

Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH.

Clin Cancer Res. 2003 Jul;9(7):2520-6.

PMID:
12855626
[PubMed - indexed for MEDLINE]
Free Article
4.

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.

Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H.

Cancer. 2007 Sep 15;110(6):1295-302.

PMID:
17623836
[PubMed - indexed for MEDLINE]
Free Article
5.
6.

A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.

Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde H, Giaccone G.

Clin Cancer Res. 2007 Jun 15;13(12):3642-51.

PMID:
17575229
[PubMed - indexed for MEDLINE]
Free Article
7.

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.

Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P.

Invest New Drugs. 2011 Jun;29(3):473-80. doi: 10.1007/s10637-009-9381-y. Epub 2010 Jan 15.

PMID:
20082116
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.

Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O'Flaherty C, Bloss J, Chi D, Spriggs D.

Clin Cancer Res. 2004 May 1;10(9):2962-7.

PMID:
15131031
[PubMed - indexed for MEDLINE]
Free Article
9.

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

Milojkovic Kerklaan B, DiƩras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart MJ, Schellens JH, Awada A.

Cancer Chemother Pharmacol. 2013 Jan;71(1):53-62. doi: 10.1007/s00280-012-1972-1. Epub 2012 Sep 29. Erratum in: Cancer Chemother Pharmacol. 2013 Feb;71(2):553. Kerklaan, Bojana Milojkovic [corrected to Milojkovic Kerklaan, Bojana].

PMID:
23053259
[PubMed - indexed for MEDLINE]
10.

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G.

Clin Cancer Res. 2012 Apr 15;18(8):2344-51. doi: 10.1158/1078-0432.CCR-11-2425. Epub 2012 Feb 27.

PMID:
22371451
[PubMed - indexed for MEDLINE]
Free Article
11.

Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.

Ready NE, Lipton A, Zhu Y, Statkevich P, Frank E, Curtis D, Bukowski RM.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):576-83.

PMID:
17255280
[PubMed - indexed for MEDLINE]
Free Article
12.

A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.

Kakolyris SS, Kouroussis C, Koukourakis M, Kalbakis K, Mavroudis D, Vardakis N, Georgoulias V.

Anticancer Res. 2002 May-Jun;22(3):1891-6.

PMID:
12168889
[PubMed - indexed for MEDLINE]
13.

Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.

Zhu Y, Statkevich P, Cutler DL.

Int J Clin Pharmacol Ther. 2007 Oct;45(10):539-47.

PMID:
17966839
[PubMed - indexed for MEDLINE]
14.

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.

Wong NS, Meadows KL, Rosen LS, Adjei AA, Kaufmann SH, Morse MA, Petros WP, Zhu Y, Statkevich P, Cutler DL, Meyers ML, Hurwitz HI.

Cancer Invest. 2011 Nov;29(9):617-25. doi: 10.3109/07357907.2011.621912.

PMID:
22011284
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.

Sayar H, Shen Z, Lee SJ, Royce M, Rabinowitz I, Lee F, Smith H, Eberhardt S, Maestas A, Lu H, Verschraegen C.

Invest New Drugs. 2009 Apr;27(2):153-8. doi: 10.1007/s10637-008-9172-x. Epub 2008 Sep 5.

PMID:
18773144
[PubMed - indexed for MEDLINE]
16.

A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.

Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Nikolaidou M, Samonis G, Marselos M, Georgoulias V.

Ann Oncol. 2003 Feb;14(2):304-12.

PMID:
12562660
[PubMed - indexed for MEDLINE]
Free Article
17.

A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.

Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab T.

Invest New Drugs. 2013 Jun;31(3):685-95. doi: 10.1007/s10637-012-9863-1. Epub 2012 Jul 31.

PMID:
22847785
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.

Rachamalla R, Malamud S, Grossbard ML, Mathew S, Dietrich M, Kozuch P.

Anticancer Drugs. 2004 Mar;15(3):211-7.

PMID:
15014353
[PubMed - indexed for MEDLINE]
19.

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.

Siegel-Lakhai WS, Crul M, Zhang S, Sparidans RW, Pluim D, Howes A, Solanki B, Beijnen JH, Schellens JH.

Br J Cancer. 2005 Nov 28;93(11):1222-9.

PMID:
16251868
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.

Bhargava P, Marshall JL, Fried K, Williams M, Lefebvre P, Dahut W, Hanfelt J, Gehan E, Figuera M, Hawkins MJ, Rizvi NA.

Cancer Chemother Pharmacol. 2001 Aug;48(2):95-103.

PMID:
11561784
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk